PT4103566T - Compostos de pirimidina fundidos como moduladores de kcc2 - Google Patents
Compostos de pirimidina fundidos como moduladores de kcc2Info
- Publication number
- PT4103566T PT4103566T PT217121458T PT21712145T PT4103566T PT 4103566 T PT4103566 T PT 4103566T PT 217121458 T PT217121458 T PT 217121458T PT 21712145 T PT21712145 T PT 21712145T PT 4103566 T PT4103566 T PT 4103566T
- Authority
- PT
- Portugal
- Prior art keywords
- kcc2
- modulators
- pyrimidine compounds
- fused pyrimidine
- fused
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989104P | 2020-03-13 | 2020-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4103566T true PT4103566T (pt) | 2023-11-09 |
Family
ID=74874882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT217121458T PT4103566T (pt) | 2020-03-13 | 2021-03-12 | Compostos de pirimidina fundidos como moduladores de kcc2 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20230151013A1 (ko) |
| EP (1) | EP4103566B1 (ko) |
| JP (1) | JP2023517680A (ko) |
| KR (1) | KR20220152319A (ko) |
| CN (1) | CN115298182A (ko) |
| AU (1) | AU2021234134A1 (ko) |
| BR (1) | BR112022018173A2 (ko) |
| CA (1) | CA3171192A1 (ko) |
| CL (1) | CL2022002386A1 (ko) |
| CO (1) | CO2022012884A2 (ko) |
| DK (1) | DK4103566T3 (ko) |
| ES (1) | ES2962136T3 (ko) |
| FI (1) | FI4103566T3 (ko) |
| HR (1) | HRP20231314T1 (ko) |
| HU (1) | HUE064037T2 (ko) |
| IL (1) | IL296265A (ko) |
| LT (1) | LT4103566T (ko) |
| MX (1) | MX2022011354A (ko) |
| PE (1) | PE20230106A1 (ko) |
| PL (1) | PL4103566T3 (ko) |
| PT (1) | PT4103566T (ko) |
| RS (1) | RS64823B1 (ko) |
| SI (1) | SI4103566T1 (ko) |
| WO (1) | WO2021180952A1 (ko) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022407047A1 (en) * | 2021-12-08 | 2024-07-25 | Kineta, Inc. | Bicyclic heteroarenes and methods of their use |
| CN117843618A (zh) * | 2022-08-29 | 2024-04-09 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090099195A1 (en) * | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| AU2015222865B2 (en) * | 2014-02-28 | 2019-06-20 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| WO2018217766A1 (en) * | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| JP2021525707A (ja) * | 2018-05-25 | 2021-09-27 | ザ チルドレンズ メディカル センター コーポレーション | 脊髄損傷を処置するための方法 |
-
2021
- 2021-03-12 FI FIEP21712145.8T patent/FI4103566T3/fi active
- 2021-03-12 MX MX2022011354A patent/MX2022011354A/es unknown
- 2021-03-12 PT PT217121458T patent/PT4103566T/pt unknown
- 2021-03-12 LT LTEPPCT/EP2021/056393T patent/LT4103566T/lt unknown
- 2021-03-12 IL IL296265A patent/IL296265A/en unknown
- 2021-03-12 CA CA3171192A patent/CA3171192A1/en active Pending
- 2021-03-12 KR KR1020227035465A patent/KR20220152319A/ko active Search and Examination
- 2021-03-12 BR BR112022018173A patent/BR112022018173A2/pt unknown
- 2021-03-12 ES ES21712145T patent/ES2962136T3/es active Active
- 2021-03-12 US US17/911,051 patent/US20230151013A1/en active Pending
- 2021-03-12 EP EP21712145.8A patent/EP4103566B1/en active Active
- 2021-03-12 SI SI202130073T patent/SI4103566T1/sl unknown
- 2021-03-12 RS RS20231022A patent/RS64823B1/sr unknown
- 2021-03-12 PL PL21712145.8T patent/PL4103566T3/pl unknown
- 2021-03-12 WO PCT/EP2021/056393 patent/WO2021180952A1/en active Application Filing
- 2021-03-12 JP JP2022554784A patent/JP2023517680A/ja active Pending
- 2021-03-12 DK DK21712145.8T patent/DK4103566T3/da active
- 2021-03-12 CN CN202180020856.3A patent/CN115298182A/zh active Pending
- 2021-03-12 HR HRP20231314TT patent/HRP20231314T1/hr unknown
- 2021-03-12 PE PE2022001943A patent/PE20230106A1/es unknown
- 2021-03-12 HU HUE21712145A patent/HUE064037T2/hu unknown
- 2021-03-12 AU AU2021234134A patent/AU2021234134A1/en active Pending
-
2022
- 2022-09-01 CL CL2022002386A patent/CL2022002386A1/es unknown
- 2022-09-09 CO CONC2022/0012884A patent/CO2022012884A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20230106A1 (es) | 2023-01-25 |
| CN115298182A (zh) | 2022-11-04 |
| HUE064037T2 (hu) | 2024-03-28 |
| FI4103566T3 (fi) | 2023-10-20 |
| KR20220152319A (ko) | 2022-11-15 |
| US20230151013A1 (en) | 2023-05-18 |
| CL2022002386A1 (es) | 2023-04-28 |
| IL296265A (en) | 2022-11-01 |
| ES2962136T3 (es) | 2024-03-15 |
| CA3171192A1 (en) | 2021-09-16 |
| HRP20231314T1 (hr) | 2024-02-16 |
| EP4103566A1 (en) | 2022-12-21 |
| SI4103566T1 (sl) | 2024-04-30 |
| PL4103566T3 (pl) | 2024-02-05 |
| BR112022018173A2 (pt) | 2022-10-25 |
| RS64823B1 (sr) | 2023-12-29 |
| LT4103566T (lt) | 2023-11-10 |
| DK4103566T3 (da) | 2023-10-30 |
| CO2022012884A2 (es) | 2022-10-11 |
| WO2021180952A9 (en) | 2021-12-16 |
| WO2021180952A1 (en) | 2021-09-16 |
| MX2022011354A (es) | 2022-11-30 |
| JP2023517680A (ja) | 2023-04-26 |
| EP4103566B1 (en) | 2023-10-04 |
| AU2021234134A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3740478C0 (en) | CONDENSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | |
| IL292156A (en) | Transduced azacils as trmp8 modulators | |
| HK1238627A1 (zh) | 作為離子通道調節劑的稠合雜環化合物 | |
| EP3356356A4 (en) | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | |
| EP4029479A4 (en) | CAGE HOLDER FOR SPINAL FUSION CAGE | |
| HK1224283A1 (zh) | 作為離子通道調節劑的稠合雜環化合物 | |
| IL285246A (en) | Substitute bicyclic compounds as modular farnesoid x receptors | |
| SG11202101499UA (en) | Heterocyclic compounds as ahr modulators | |
| EP3600328A4 (en) | MERGED TRIAZOLO-PYRIMIDINE COMPOUNDS WITH USEFUL PHARMACEUTICAL APPLICATION | |
| EP3509588A4 (en) | BICYCLIC COMPOUNDS USEFUL AS MODULATORS OF GPR120 | |
| PT4103566T (pt) | Compostos de pirimidina fundidos como moduladores de kcc2 | |
| EP3768670A4 (en) | IMIDAZOLIDIN-2-ON COMPOUNDS AS PRMT5 MODULATORS | |
| IL290367A (en) | Fused ring heteroaryl compounds as ripk1 inhibitors | |
| EP3880204A4 (en) | IMPROVED SYNTHETIC PROCESSES FOR THE PRODUCTION OF CONDENSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | |
| SG11202108796YA (en) | Substituted bicyclic compounds as farnesoid x receptor modulators | |
| EP3373051A4 (en) | COMPOSITION FOR PRODUCING AN OPTICAL WAVEGUIDE | |
| EP3994434A4 (en) | PHOTONIC STABILIZATION CIRCUIT | |
| EP3661919A4 (en) | SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS AND USES THEREOF | |
| EP3275874A4 (en) | Fused heterocyclic compound | |
| IL285570A (en) | Bicyclic compounds substituted as farnesoid receptor modulators | |
| HK1225728B (zh) | 作為離子通道調節劑的融合雜環化合物 | |
| IL285482A (en) | Compounds containing pyrimidine derivatives | |
| EP3630100A4 (en) | CONDENSED BICYCLIC COMPOUNDS | |
| CA188056S (en) | Vial adaptor | |
| GB201918974D0 (en) | Gpr52 modulator compounds |